Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 31

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 31
---
 discretion over the use of proceeds from sales of ourDepositary Shares made pursuant to the Purchase Agreement, including for any of the purposes described in the section entitled “ Use of Proceeds,” and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net proceeds from this offering as set forth in “ Use of Proceeds,” we are not obligated to do so. The failure by us to apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of ourDepositary Shares.

Future resales and/or issuances of our Depositary Shares, including pursuant to this prospectus, or the perception that such sales may occur, may cause the market price of our shares to drop significantly.

On January 17, 2025, we entered
into the Purchase Agreement, pursuant to which the Selling Shareholder shall, subject to the restrictions and satisfaction of the conditions
in the Purchase Agreement, purchase from us up to an aggregate of $35.0 million of Depositary Shares, upon the terms and subject to the
conditions and limitations set forth in the Purchase Agreement.

The Depositary Shares that
may be issued under the Purchase Agreement may be sold, subject to the restrictions and satisfaction of the conditions in the Purchase
Agreement, by us to the Selling Shareholder at our discretion from time to time from the date of effectiveness of the registration statement
of which this prospectus forms a part until a Termination Event.

The purchase price for Depositary
Shares that we may sell to the Selling Shareholder under the Purchase Agreement will fluctuate based on the trading price of shares of
our Depositary Shares. Depending on market liquidity at the time, sales of Depositary Shares may cause the trading price of Depositary
Shares to decrease. We generally have the right to control the timing and amount of any future sales of Depositary Shares to the Selling
Shareholder. Additional sales of Depositary Shares, if any, to the Selling Shareholder will depend upon market conditions and other factors
to be determined by us. We may ultimately decide to sell to the Selling Shareholder all, some or none of the additional Depositary Shares
that may be available for us to sell pursuant to the Purchase Agreement. If and when we